• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Mind Medicine Mindmed Inc (NQ: MNMD )

    8.420 +0.230 (+2.81%)
    Streaming Delayed Price Updated: 3:17 PM EST, Nov 13, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Mind Medicine Mindmed Inc

    < Previous 1 2 3 4 5 6 7 8 9
    ...
    31 32 Next >
    MindMed Announces Constructive End-of-Phase 2 Meeting with U.S. FDA for MM120 in Generalized Anxiety Disorder (GAD)
    From Mind Medicine
    Via Business Wire
    Wall Street Favorites: 3 Penny Stocks With Strong Buy Ratings for June 2024
    Discover top strong buy penny stocks, poised for impressive gains as market indices climb, offering unique opportunities. 
    Via InvestorPlace
    Largest Psychedelic Compound Based Drug Stocks Fell 13% Last Week - Here's Why
    Stocks for companies developing psychedelic treatments fell last Wednesday after advisers to the Food and Drug Administration voted against a mental-health therapy using the drug MDMA. 
    Via Talk Markets
    Psychedelic Stocks Trip Up After FDA Advisors Reject MDMA For PTSD Treatment
    FDA panel rejects MDMA therapy for PTSD, citing lack of evidence for benefits outweighing risks. Psychedelic stocks take a hit, with CYBN, MNMD, and ATAI down. FDA not bound by decision. 
    Via Benzinga
    Exposures Product Safety
    Why Lands' End Shares Are Trading Lower? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
    Via Benzinga
    What's Going On With MindMed And Psychedelic Stocks?
    Mind Medicine (MindMed) shares are trading lower Wednesday after a Food and Drug Administration (FDA) panel rejected the approval of MDMA therapy for people with post-traumatic stress disorder (PTSD).... 
    Via Benzinga
    DouYu International Posts Q1 Results, Joins Annexon, Dollar Tree And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
    Via Benzinga
    Why Stitch Fix Shares Are Trading Higher By 18%; Here Are 20 Stocks Moving Premarket
    Via Benzinga
    MindMed to Participate in June Conferences
    From Mind Medicine Inc.
    Via Business Wire
    Largest Clinical-Stage BioTech Drug Stocks Declined Slightly Last Week
    This article highlights the performances last week and MTD of the 10 clinical-stage AI-powered and psychedelic compound-based small cap drug discovery companies along with their areas of focus in our... 
    Via Talk Markets
    The Time Traveler’s Portfolio: 3 Stocks to Buy Now for Massive Returns by 2034
    These long-term stocks to buy may seem speculative today, but so did Nvidia in 2024 -- and they may match the chipmaker's returns by 2034. 
    Via InvestorPlace
    Cannabis Meets Prescription Drugs, Steroids And Ketamine In Schedule III: What It Means, Key Stocks To Watch
    President Joe Biden's administration is moving to reschedule cannabis from Schedule I to Schedule III under the Controlled Substances Act (CSA). 
    Via Benzinga
    Topics Cannabis
    Exposures Cannabis
    Jim Cramer: This Industrial Company Is 'Absolutely Terrific', Recommends Buying Modine Manufacturing
    Regarding Hertz, Jim Cramer said, "I don't want you to sell, and I don't want you to double down. Let's just see if it can't go higher." 
    Via Benzinga
    Largest Clinical-Stage BioTech Drug Stocks Declined 3% Last Week
    Via Talk Markets
    Seritage Growth Properties Posts Q1 Loss, Joins Fortrea Holdings And Other Big Stocks Moving Lower In Monday's Pre-Market Session
    Via Benzinga
    Top Russell 2000 Picks: 3 Small-Cap Stocks to Scoop Up This May
    Some of the top Russell 2000 stocks to buy are those that few investors pay attention to but offer great potential nonetheless. 
    Via InvestorPlace
    MindMed to Participate at May Investor Conferences
    From MindMed
    Via Business Wire
    New Studies Presented at the International Society for Health Economics and Outcomes Research Meeting (ISPOR 24) Show Growing Burden and Impact of Generalized Anxiety Disorder (GAD) in the US
    From Mind Medicine (MindMed) Inc.
    Via Business Wire
    Biotech Breakthroughs: 3 Stocks on the Verge of Revolutionizing Medicine
    These biotech breakthrough stocks give investors a glimpse into medicine's future -- and massive moneymaking opportunities to boot. 
    Via InvestorPlace
    MNMD Stock Earnings: Mind Medicine Misses EPS for Q1 2024
    MNMD stock results show that Mind Medicine missed analyst estimates for earnings per share the first quarter of 2024. 
    Via InvestorPlace
    MindMed Reports First Quarter 2024 Financial Results and Business Updates
    From MindMed
    Via Business Wire
    Clinical-Stage BioTech Drug Stocks Portfolio Jumped 7% In First Week Of May
    We look at the performance of 10 clinical-stage AI-powered and psychedelic compound-based small cap drug discovery companies during the first week of May and YTD. 
    Via Talk Markets
    MindMed Presents Phase 2b Study of MM120 for Generalized Anxiety Disorder (GAD) at American Psychiatric Association (APA) Annual Meeting in New York
    From MindMed
    Via Business Wire
    MindMed to Host Conference Call and Webcast to Discuss First Quarter 2024 Financial Results and Provide Business Update
    From MindMed
    Via Business Wire
    The Top 3 Small-Cap Stocks to Buy in April 2024
    These top small-cap stocks offer investors diversification across multiple segments but boast a strong standing on their own merits. 
    Via InvestorPlace
    MindMed to Present at Upcoming May Medical Conferences
    From MindMed
    Via Business Wire
    This Small-Cap Stock Is Up 140% This Year and Here's Why It Can Go Even Higher
    For investors with a high level of risk tolerance, Mind Medicine could be an intriguing investment option. 
    Via The Motley Fool
    Clinical-Stage BioTech Drug Stocks Portfolio Went Down 9% Last Week
    A look at the 10 clinical-stage AI-powered and psychedelic compound-based small-cap drug discovery companies in our Clinical-Stage BioTech Drug Stocks Portfolio, their stock performances last week and... 
    Via Talk Markets
    Jim Cramer Slams Political Blocking Of 'LSD-Derived Antidepressants,' Citing Strong Test Data 'Showing They Worked'
    Via Benzinga
    Psychedelics Headlines: Dementia Prevention, Psychological Flexibility, Ancient Romans' Trips And More
    Via Benzinga
    < Previous 1 2 3 4 5 6 7 8 9
    ...
    31 32 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.